Peptide Regulatory Status: U.S. Approval and Compounding

A peptide's clinical evidence, FDA approval, and compounding status are separate questions. Approval applies to a specific product and indication. A published trial, research-use label, or nomination for a compounding list does not authorize an unapproved product for clinical use. This U.S.-focused guide was reviewed on September 30, 2026; check the linked FDA records for later changes.

Verify an FDA-approved product

Search Drugs@FDA for the exact brand, active ingredient, formulation, and label. The label, rather than a molecule-level summary, defines the approved indication, route, population, warnings, and dosing instructions. Examples illustrate why the product matters:

This is an example list, not a complete catalog of approved peptide drugs. Thymalfasin's approval outside the United States does not make it an FDA-approved U.S. drug. The FDA Orange Book and Drugs@FDA provide product records for verification.

What 503A and 503B compounding mean

Section 503A sets conditions for pharmacy or physician compounding; section 503B sets different conditions for registered outsourcing facilities. A compounded drug is not FDA-approved, even when the active ingredient is present in an approved drug. Eligibility depends on the statute, the exact bulk substance, applicable lists, shortage status, and restrictions on essentially copying approved products.

Do not read “a pharmacy offers it” as proof that a peptide is eligible for either pathway. FDA's GLP-1 shortage and compounding policy explains the consequences of resolved shortages and the restrictions on essentially copying approved products. On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list; the announcement was a proposal, not a final rule. It did not itself resolve every 503A question.

FDA safety-risk categories are not approval decisions

FDA's current page on nominated bulk substances with potential significant safety risks places BPC-157 and AOD-9604 under “nominated but withdrawn.” It lists ipamorelin acetate under the 503B Category 2 interim policy. The page also describes safety and characterization concerns for several other research peptides. A withdrawn nomination does not mean FDA approved a substance or found it safe for human use.

For a particular substance, read the substance entry and the separate 503A and 503B bulk-substance lists. Status can change, and a broad “all peptides” table obscures these distinctions.

Investigational peptides and trial registration

Retatrutide, zenagamtide, eloralintide, VK2735, and petrelintide have published or registered clinical research but no FDA-approved U.S. product identified in this review. A ClinicalTrials.gov record describes a study; it is not an FDA authorization to market a drug. Peer-reviewed efficacy results likewise do not establish an approved dose, formulation, or benefit-risk profile.

“Research use only” on a seller's label does not create a blanket legal category or make self-administration safe. FDA assesses products based on their intended use and applicable law; see the agency's unapproved drugs overview.

Sport and other jurisdictions

Anti-doping rules are distinct from FDA drug approval. Athletes should check the applicable year's World Anti-Doping Agency Prohibited List and any sport-specific rules for the exact substance and route. This page does not assign permanent WADA or non-U.S. legal classifications to individual peptides; those need a current, jurisdiction-specific primary source.

Verification checklist

1. Find the exact product in Drugs@FDA and read its current label.
2. If it is investigational, identify the exact molecule and trial in ClinicalTrials.gov, then inspect published results separately.
3. For compounding, check the substance and pathway on FDA's bulk-substance hub and the current shortage/copying policy.
4. For sport or another country, use that authority's current rule or regulator record instead of extrapolating from U.S. approval.